Brief: Nanobiotix Sees Available Capital Funding Operations Into Q4 2023 At Least

Nanobiotix SA

19/05/2022 06:58

May 19 (Reuters) - Nanobiotix SA  NANOB.PA :
    * SAID ON WEDNESDAY CASH POSITION TOTALING EUR 70.6 MILLION
AS OF
MARCH 31, 2022
    * ANTICIPATES THAT AVAILABLE CAPITAL WILL FUND ITS
OPERATIONS
INTO, AT LEAST, Q4 OF 2023
    * ON-TRACK TO ACTIVATE FIRST US CLINICAL TRIAL SITES IN
ON-GOING
PIVOTAL PHASE III GLOBAL REGISTRATION STUDY, NANORAY-312, IN
LOCALLY ADVANCED HEAD AND NECK SQUAMOUS CELL CARCINOMA
(LA-HNSCC) IN Q3 2022
    * RECEIVED PRELIMINARY FEEDBACK FROM FDA INFORMING
DEVELOPMENT OF
PIVOTAL PHASE III PROTOCOL FOR NBTXR3 IN COMBINATION WITH
ANTI-PD-1 THERAPY, PROTOCOL SUBMISSION PLANNED IN Q1 2023
    * EXPLORING BROADER DEBT RESTRUCTURING TO POTENTIALLY EXTEND
OPERATING RUNWAY FURTHER

Source text for Eikon:  ID:nBw2Lxh8Na 
Further company coverage:  NANOB.PA 

 (Gdansk Newsroom)
 ((Gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))